…
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
BeyondSpring Inc is a clinical-stage biopharmaceutical company developing oncology therapies, with a lead small-molecule candidate, plinabulin, targeting prevention of chemotherapy-induced neutropenia and potential immunomodulatory benefits in cancer treatment. Long-term growth drivers include successful clinical validation in registrational studies, expansion into combination oncology indications and potential commercialization or licensing arrangements that may benefit revenue prospects.
Principal risks include trial failure or safety issues, high cash burn requiring additional financing, manufacturing and supply challenges, and competition from established supportive-care biologics and other oncology agents that could limit market adoption.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -8.62M | -8.77M | -13.92M | -36.12M | -64.64M |
| Minority interest | 13.21M | 5.57M | 0.92M | 3.00M | 4.03M |
| Net income | -7.99M | -11.12M | -21.03M | -36.28M | -68.21M |
| Selling general administrative | 4.56M | 6.11M | 10.23M | 13.01M | 30.70M |
| Selling and marketing expenses | - | - | 0.30M | - | - |
| Gross profit | -0.09M | -0.28M | -0.30M | 1.35M | 1.35M |
| Reconciled depreciation | 0.09M | 0.28M | 0.30M | 0.23M | 0.06M |
| Ebit | -8.95M | -8.75M | -13.92M | -37.24M | -66.24M |
| Ebitda | -8.86M | -8.47M | -13.62M | -35.44M | -64.72M |
| Depreciation and amortization | 0.09M | 0.28M | 0.30M | 1.80M | 1.52M |
| Operating income | -8.95M | -8.75M | -15.08M | -37.24M | -66.24M |
| Other operating expenses | 8.95M | 8.75M | 15.08M | 38.59M | 67.59M |
| Interest expense | - | - | 0.00M | 0.02M | 0.09M |
| Tax provision | 0.09M | 0.10M | 0.11M | 0.16M | 3.57M |
| Interest income | 0.08M | 0.06M | 0.42M | 0.20M | 0.10M |
| Net interest income | 0.08M | 0.06M | 0.42M | 0.18M | 0.01M |
| Income tax expense | 0.09M | 0.10M | 0.09M | 0.16M | 3.57M |
| Total revenue | 0.00M | 0.00M | 1.75M | 1.35M | 1.35M |
| Total operating expenses | 8.86M | 8.75M | 14.78M | 38.59M | 67.59M |
| Cost of revenue | 0.09M | 0.28M | 0.30M | - | - |
| Total other income expense net | 0.32M | -0.01M | 1.16M | 1.12M | 1.60M |
| Net income from continuing ops | -8.71M | -8.87M | -21.95M | -36.28M | -68.21M |
| Net income applicable to common shares | - | - | - | - | -64.18M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 25.93M | 34.31M | 24.81M | 46.22M | 81.65M |
| Other current assets | 8.32M | 25.66M | 0.48M | 0.76M | 1.02M |
| Total liab | 49.92M | 48.60M | 48.27M | 49.23M | 60.73M |
| Total stockholder equity | -32.16M | -32.90M | -26.80M | -5.98M | 26.68M |
| Other current liab | -15.71M | -16.97M | 4.17M | 3.95M | 10.02M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -408.43M | -407.43M | -396.30M | -375.28M | -342.00M |
| Other liab | - | - | - | - | 38.65M |
| Other assets | - | - | 0.00M | - | 3.12M |
| Cash | 7.79M | 2.92M | 17.75M | 34.40M | 41.62M |
| Total current liabilities | 13.58M | 11.01M | 7.96M | 7.35M | 15.15M |
| Current deferred revenue | 28.60M | 27.40M | 1.75M | 1.35M | 1.37M |
| Net debt | -7.47M | -2.33M | -13.76M | -29.43M | -38.05M |
| Short term debt | 0.32M | 0.28M | 0.63M | 0.97M | 2.11M |
| Short long term debt | - | - | - | - | 1.57M |
| Short long term debt total | 0.32M | 0.59M | 4.00M | 4.96M | 3.58M |
| Other stockholder equity | 375.66M | 373.19M | 368.60M | 368.86M | 369.20M |
| Property plant equipment | - | - | - | - | 3.41M |
| Total current assets | 20.88M | 28.58M | 18.42M | 38.52M | 75.12M |
| Net tangible assets | - | - | - | - | 26.68M |
| Short term investments | 4.78M | 0.00M | 0.19M | 2.87M | 30.74M |
| Accounts payable | 0.36M | 0.29M | 1.41M | 1.08M | 1.66M |
| Accumulated other comprehensive income | 0.60M | 1.34M | 0.89M | 0.44M | -0.52M |
| Non currrent assets other | 4.58M | 4.99M | 0.36M | 0.35M | 1.57M |
| Non current assets total | 5.05M | 5.74M | 6.39M | 7.70M | 6.53M |
| Capital lease obligations | 0.32M | 0.59M | 4.00M | 4.96M | 2.01M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 3.48M | -12.01M | -0.10M | 17.56M | -20.41M |
| Change to liabilities | - | - | - | 0.00M | 29.47M |
| Total cashflows from investing activities | 13.48M | -12.01M | -0.10M | - | -20.41M |
| Net borrowings | 0.29M | 3.91M | 0.00M | - | - |
| Total cash from financing activities | 2.27M | 26.79M | 0.00M | 3.43M | 0.00M |
| Change to operating activities | - | - | - | 7.09M | 0.19M |
| Net income | -14.22M | -11.12M | -21.03M | -36.28M | -68.21M |
| Change in cash | 4.86M | -1.70M | -16.65M | -7.23M | -67.91M |
| Begin period cash flow | 16.05M | 17.75M | 34.40M | 41.62M | 109.54M |
| End period cash flow | 7.79M | 16.05M | 17.75M | 34.40M | 41.62M |
| Total cash from operating activities | -20.02M | -16.44M | -16.47M | -27.46M | -47.24M |
| Issuance of capital stock | 2.00M | 3.00M | 0.00M | 0.00M | 0.00M |
| Depreciation | 0.09M | 0.28M | 0.30M | 0.23M | 0.06M |
| Other cashflows from investing activities | 7.30M | -11.79M | - | - | - |
| Change to inventory | -0.02M | -0.02M | 0.19M | - | 1.77M |
| Other cashflows from financing activities | 4.97M | 22.87M | 0.00M | 5.00M | 0.00M |
| Change to netincome | - | - | - | - | -1.53M |
| Capital expenditures | 0.05M | 0.22M | 0.10M | 0.03M | 2.84M |
| Change in working capital | -0.38M | -1.38M | 2.71M | 6.41M | 18.41M |
| Stock based compensation | 0.72M | 2.06M | 0.55M | 1.67M | 3.15M |
| Other non cash items | -6.24M | -6.29M | 0.99M | 0.51M | 0.55M |
| Free cash flow | -20.07M | -16.67M | -16.57M | -27.50M | -50.09M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BYSI BeyondSpring Inc |
0.00 0.03% |
0.60 | - | 10.54 | 45.99 | 5.38 | 41.79 | 0.05 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
100 Campus Drive, Florham Park, NJ, United States, 07932
646 305 6387
44
| Name | Title | Year Born |
|---|---|---|
| Dr. Lan Huang | Co-Founder, Chairman & CEO | 1971 |
| Dr. G. Kenneth Lloyd | Chief Scientific Officer | 1944 |
| Dr. Ramon W. Mohanlal | Exec. VP of R&D, Chief Medical Officer and Director | 1958 |
| Mr. Linqing Jia | Co-Founder | NA |
| Stephen Kilmer | Head of Investor Relations | NA |
| Mr. Gregg Russo | Sr. VP of HR | NA |
| Dr. Lan Huang Ph.D. | Co-Founder, Chairman & CEO | 1971 |
| Dr. June Lu Ph.D. | Chief Scientific Officer | NA |
| Mr. Gregg Russo | Senior Vice President of Human Resources | NA |
| Dr. June Lu Ph.D. | Chief Scientific Officer | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.